Scarica l'app Stockscreener
16.78
4.77%
-0.84
Dopo l'orario di chiusura:
16.78
Precedente Chiudi:
$17.62
Aprire:
$17.6
Volume 24 ore:
819.73K
Relative Volume:
0.88
Capitalizzazione di mercato:
$1.11B
Reddito:
Utile/perdita netta:
$-137.95M
Rapporto P/E:
-6.6519
EPS:
-2.5226
Flusso di cassa netto:
$-107.11M
1 W Prestazione:
-4.11%
1M Prestazione:
-23.73%
6M Prestazione:
-29.88%
1 anno Prestazione:
-10.17%
Intervallo 1D:
$16.69
$17.78
Intervallo di 1 settimana:
$16.69
$17.99
Portata 52W:
$13.70
$30.99
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Nome
Bicara Therapeutics Inc
Settore
Industria
Telefono
617-468-4219
Indirizzo
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
16.78 | 1.11B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-19 | Iniziato | BMO Capital Markets | Outperform |
| 2026-05-11 | Iniziato | Guggenheim | Buy |
| 2026-03-25 | Iniziato | BofA Securities | Buy |
| 2026-01-29 | Iniziato | Citizens JMP | Mkt Perform |
| 2026-01-08 | Iniziato | BTIG Research | Buy |
| 2025-12-18 | Iniziato | Mizuho | Neutral |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-05-23 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Iniziato | Wells Fargo | Underweight |
| 2025-02-06 | Iniziato | Wedbush | Outperform |
| 2024-12-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-10-08 | Iniziato | Stifel | Buy |
| 2024-10-08 | Iniziato | TD Cowen | Buy |
Mostra tutto
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
T. Rowe Price lists 2.8 million shares in Bicara Therapeutics (BCAX) ownership amendment. - Stock Titan
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
LB Pharmaceuticals Inc (LBRX) Stock Price & News - Syfe
Bicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Detailed Stock Data - The Chronicle-Journal
Cantor Fitzgerald reiterates Overweight on Bicara stock By Investing.com - Investing.com Australia
Bicara Therapeutics' President Ryan Cohlhepp Reports Stock Option Exercise and Share Sales in Form 4 Filing - Kalkine Media
Bicara interim CEO sells 17,500 shares after option exercise | BCAX Insider Trading - Stock Titan
Cantor Fitzgerald reiterates Overweight on Bicara stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight on Bicara stock By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Overweight on Bicara stock By Investing.com - Investing.com UK
Cantor Fitzgerald reiterates Overweight on Bicara stock - Investing.com
JonesTrading Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $30 - moomoo.com
New Bicara (NASDAQ: BCAX) share sale planned after July and August deals - Stock Titan
BCAX Form 4 FilingsBicara Therapeutics Inc. SEC Form 4 - Stock Titan
BCAX Form 4 FilingsBicara Therapeutics Inc. SEC Form 4 - Stock Titan
BCAX 424B FilingsBicara Therapeutics Inc. SEC 424B - Stock Titan
BCAX 8-K FilingsBicara Therapeutics Inc. SEC 8-K - Stock Titan
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Bicara Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Boston biotech Bicara signs sublease for Wayfair space - The Business Journals
Bicara (BCAX) Financial Results: Reported EPS Tops Expectations in the Latest Session; Share Move: The Stock Records a 0.50% Decrease in the Current UpdateDividend Cut Risk - vinanet.vn
How Bicara’s Leadership Overhaul and CEO Succession Plan Could Shape Bicara Therapeutics (BCAX) Investors - webull.com
Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com
Citizens reiterates Bicara Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com
Jennifer Larson Net Worth (2026) - GuruFocus
Bicara Therapeutics (NASDAQ:BCAX) Raised to "Strong-Buy" at BMO Capital Markets - MarketBeat
BMO Capital Initiates Bicara Therapeutics at Outperform - Moomoo
Bicara Therapeutics Initiated at Outperform by BMO Capital - Moomoo
Bicara Therapeutics Inc. (BCAX) Stock Price, News, Quote & History - Yahoo Finance
BICARA THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $35 - Bitget
Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul - Yahoo Finance
BMO starts Bicara Therapeutics stock at Outperform on cancer drug potential - Investing.com India
BMO starts Bicara Therapeutics stock at Outperform on cancer drug potential - Investing.com Canada
BMO starts Bicara Therapeutics stock at Outperform on cancer drug potential - Investing.com
BMO Capital Initiates Bicara Therapeutics at Outperform - marketscreener.com
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf FilingHas The Bull Case Changed? - Sahm
SCS Capital Management LLC Purchases New Shares in Bicara Therapeutics Inc. $BCAX - MarketBeat
BCAX Stock Price and Chart — NASDAQ:BCAX - TradingView
Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf FilingHas The Bull Case Changed? - webull.com
Walleye Capital LLC Makes New $10.49 Million Investment in Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) awards 285,000 stock options to CFO Jennifer Larson - Stock Titan
Bicara Therapeutics (BCAX) CFO Jennifer Larson submits initial Form 3 - Stock Titan
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bicara Therapeutics Inc Azioni (BCAX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Cohlhepp Ryan | President, COO & Interim CEO |
Sep 08 '26 |
Sale |
22.90 |
17,500 |
400,716 |
181,641 |
| Hyep Ivan | Officer |
Sep 08 '26 |
Proposed Sale |
22.64 |
12,500 |
283,000 |
0 |
| Cohlhepp Ryan | Officer |
Sep 08 '26 |
Proposed Sale |
22.64 |
17,500 |
396,200 |
0 |
| Hyep Ivan | Chief Financial Officer |
Aug 10 '26 |
Option Exercise |
3.79 |
12,500 |
47,372 |
142,355 |
| Hyep Ivan | Chief Financial Officer |
Aug 10 '26 |
Sale |
27.97 |
12,500 |
349,591 |
129,855 |
| Mazumdar Claire | Chief Executive Officer |
Aug 10 '26 |
Option Exercise |
3.79 |
10,000 |
37,898 |
372,152 |
| Mazumdar Claire | Chief Executive Officer |
Aug 10 '26 |
Sale |
27.98 |
10,000 |
279,750 |
362,152 |
| Cohlhepp Ryan | President and COO |
Aug 10 '26 |
Option Exercise |
3.79 |
18,750 |
71,059 |
200,391 |
| Cohlhepp Ryan | President and COO |
Aug 10 '26 |
Sale |
27.98 |
18,750 |
524,533 |
181,641 |
| Hyep Ivan | Officer |
Aug 10 '26 |
Proposed Sale |
27.83 |
12,500 |
347,875 |
0 |
0.00%
4.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):